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Abstract:
Environmental particulate pollutants (PM) adversely affect human health, but the molecular basis is poorly understood. The ion channel TRPV1 has been implicated as a sensor for environmental PM and a mediator of adverse events in the respiratory tract. The objectives of this study were: to determine if TRPV1 can distinguish chemically and physically unique PM that represent important sources of air pollution; to elucidate the molecular basis of TRPV1 activation by PM; and to ascertain the contributions of TRPV1 to human lung cell and mouse lung tissue responses exposed to an insoluble PM agonist, coal fly ash (CFA1). The major findings of this study are: TRPV1 is activated by some, but not all of the prototype PM materials evaluated, with responses to CFA1>diesel exhaust PM>crystalline silica; TRPM8 is also robustly activated by CFA1, while other TRP channels expressed by airway sensory neurons and lung epithelial cells that may also be activated by CFA1, including TRPA1, C4α, M2, V2, V3, or V4, were either slightly (TRPA1) or not activated by CFA1; activation of TRPV1 by CFA1 occurs via cell surface interactions between the solid components of CFA1 and specific amino acid residues of TRPV1 that are localized in the putative pore-loop region; and activation of TRPV1 by CFA1 is not exclusive in mouse lungs, but represents a pathway by which CFA1 impacts the expression of selected genes in lung epithelial cells and airway tissue.
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immunomodulatory cytokines and chemokines including IL-6, IL-8 and TNFα, and cell death in vitro (Veronesi et al., 1999a; Veronesi et al., 1999b; Oortgiesen et al., 2000; Agopyan et al., 2003a; Agopyan et al., 2003b; Reilly et al., 2003; Reilly et al., 2005; Thomas et al., 2011) .
Many acute adverse responses to concentrated urban PM have also been associated with activation of capsaicin-sensitive (i.e., TRPV1 positive) bronchopulmonary C-fiber neurons that initiate pulmonary reflex responses including cough and reduced compliance, as well as edema.
These neurons release substance P (SP) and neurokinin A (NKA), among other substances, that promote abrupt changes in cardiopulmonary function, lung-vascular fluid barrier function, and stimulate pro-inflammatory mediator production by non-neuronal cells (Reilly, 2010) .
While existing literature strongly supports a role for TRPV1 as a mediator of several major adverse effects of PM in the lung and on respiratory function, it is not clear how PM interacts with TRPV1 to elicit such responses, whether TRPV1 is a selective or indiscriminant sensor of environmental PM (i.e., do other TRP or calcium channels also detect PM and promote toxicity), or if activation of TRPV1 is directly coupled with processes that influence deleterious changes in airway homeostasis. The objectives of this study were to determine if TRPV1 can distinguish chemically and physically unique forms of PM, to elucidate the molecular basis of TRPV1 activation by such PM, and to ascertain the contributions of TRPV1 to potentially deleterious lung cell and tissue responses elicited by treatment with a moderately selective PM agonist.
Materials and Methods:
Chemicals and Reagents: n-Vanillylnonanamide (nonivamide; a capsaicin analogue), (-) menthol, icilin, allyl isothiocyanate (AITC), hydrogen peroxide (H 2 O 2 ; 30%), carvacrol, Δ 9 -tetrahydrocannabinol (THC), GSK1016790A, carbachol (carbamoyl choline), ionomycin, This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on December 9, 2011 as DOI: 10.1124 at ASPET Journals on July 6, 2017 molpharm.aspetjournals.org Downloaded from EGTA, and ruthenium red were purchased from Sigma-Aldrich (St. Louis, MO) and (N-(4-tert-butylbenzyl)-N'-(1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl)thiourea) was synthesized by Dr. Jeewoo Lee. The structure of LJO-328 is also available in the following reference (Reilly et al., 2005) . H 2 O 2 concentrations were determined spectrophotometrically using the extinction coefficient ε 240 =39.4 M -1 cm -1 . PCR primers were synthesized by the University of Utah DNA synthesis core facility.
Cells and Cell Culture: Immortalized human bronchial epithelial cells (BEAS-2B) were
purchased from American Type Culture Collection (Manassas, VA). TRPV1 over-expressing BEAS-2B (TRPV1-OE) cells were generated as previously described (Reilly et al., 2003) .
BEAS-2B and TRPV1-OE cells were cultured in LHC-9 media (Invitrogen). Primary normal human bronchial epithelial cells (NHBE), were purchased from Lonza (Walkersville, MD), and were cultured in BEGM media. Culture flasks for all three cell types were pre-coated with LHC basal media fortified with 30 μ g/mL collagen, 10 μ g/mL fibronectin, and 10 μ g/mL BSA. Cells were maintained between 30 and 90% maximum density in a humidified incubator at 37 o C with a 5% CO 2 :95% air atmosphere, and were sub-cultured using trypsin.
Particulate Materials (PM):
Six chemically and physically different combustionderived, soil-derived, and manufactured PM, representative of PM that are found in ambient air, were selected as a test set for identifying TRPV1 agonists, based on their environmental relevance, and variable effects on lung cells and/or tissue, as described by our group and others (Veronesi et al., 1999a; Veronesi et al., 1999b; Agopyan et al., 2003a; Agopyan et al., 2003b; Veranth et al., 2004; Smith et al., 2006; Veranth et al., 2006; Veranth et al., 2008; Deering-Rice et al., 2011) . CFA1 is a size-fractionated sample of coal fly ash collected from a power plant in
Utah. This material is derived from combustion of low-sulfur bituminous coal and represents This article has not been copyedited and formatted. The final version may differ from this version. Human TRPA1, C4α, M8, the N-terminal truncated TRPM8 Δ1-801 variant, V1, V2, V3, and V4 were cloned as previously described (Reilly et al., 2003; Sabnis et al., 2008; Deering-Rice et al., 2011) . Sequence verified plasmid DNA was transfected into HEK-293 cells grown to confluence in 96-well culture dishes pre-coated for 2h with 1% gelatin using 175 ng/well plasmid DNA and Lipofectamine 2000 (Invitrogen) at a 2:1 lipid to DNA ratio in 50 μL
OptiMem media (Invitrogen) for 4h upon which 100 μL DMEM:F12 media containing 5% Fetal Bovine Serum was added for an additional 20h. The media was replaced and cells were assayed 24h later or selected for stable over-expression by diluting and culturing in media containing 400μg/mL Geneticin. TRPA1, C4α, V2, V3, V4, and M8 stable over-expressing cells were generated in our laboratory as previously described (Deering-Rice et al., 2011) while TRPM2
over-expressing cells were provided by Dr. Yasuo Mori (Kyoto University, Kyoto, Japan).
TRPV1 and the TRPM8 Δ1-801 variant were transiently over-expressed in HEK-293 using the methods described above, and TRPV1 was stably over-expressed in BEAS-2B cells as previously described (Reilly et al., 2003) . Site-directed mutagenesis of TRPV1 was performed using the QuickChange XL kit (Stratagene, La Jolla, CA) and mutants were compared to wildtype receptors using transient over-expression in HEK-293 cells with normalization of data using nonivamide (25 μM) as the agonist. Pre-treatment of TRPV1-OEcells for 24h with the TRPV1 antagonist LJO-328 at 5 μM, as previously described (Johansen et al., 2006) , was used to enrich TRPV1 at the cell surface to determine if CFA1 preferentially activated TRPV1 at the cell surface, as suggested by prior studies of TRPV1-PM interactions (Oortgiesen et al., 2000; Veronesi et al., 2002; Agopyan et al., 2003a; Agopyan et al., 2003b; Veronesi et al., 2003; Agopyan et al., 2004) , or if CFA1 uptake or CFA1-derived materials released into the treatment media were the agonists. Cell surface proteins were isolated from two confluent T-75 flasks of cells/group using the Pierce Sulfo- RNeasy mini kit (Qiagen, Valencia, CA) and 2.5 μ g of the total RNA was converted to cDNA using Superscript III (Invitrogen). The resulting cDNA was either assayed for gene expression using multiplex PCR followed by agarose gel electrophoresis and gel densitometry, as previously This article has not been copyedited and formatted. The final version may differ from this version. Histology: Lungs were accessed and the trachea was cannulated with a blunt-ended needle and the lungs were inflated 10% neutral-buffered formalin at ~20 cm fixed pressure. The lungs were fixed for ~5 min, the trachea tied off, and the entire respiratory tract removed and placed in 10% neutral buffered formalin. Cross sections (~4-5 mm thick) from the bronchial insertion point to the lower portion of the left lobe were taken and used to prepare serial 5 μm sections for staining with Hematoxylin and Eosin. Tissue sectioning and staining was performed by ARUP Laboratories (Salt Lake City, UT).
Airway Segmentation: Male CF1 mice were treated i.t. with nonivamide (0.5 mg/kg; PBS containing 4% v/v ethanol) or CFA1 (250 μg), and the respiratory tissue was inflated with RNALater, collected as described above, and stored at 4 o C. Within 48h, the lungs were dissected in a bath of RNALater and the trachea, main bronchi, bronchioles from the main bronchus (generation 3) into the parenchyma (as far as possible), and alveolar regions were collected from the left lobe. Whole lung samples were the right cranial and middle lobes.
Tissues were stored at -80 o C until mRNA isolation using the Trizol-Plus kit (Invitrogen), as described above. Prior to PCR analysis, mRNA from these samples was amplified. Briefly, total RNA (1μg) was amplified using the Message Amp II RNA amplification kit (Ambion, Austin, This article has not been copyedited and formatted. The final version may differ from this version. 
Results:
Identification of environmental PM agonists of TRPV1 was achieved by measuring calcium influx into HEK-293 cells transiently transfected with human TRPV1 ( Figure 1A ). The known TRPV1 agonist nonivamide was used as positive control, and ionomycin was used to assess maximum cell fluorescence and to normalize the results for the various treatments, as described in methods. PM treatments were applied at a concentration of 0.73 mg/ml, which in previous experiments has been shown to produce a maximum TRP-dependent response (i.e., Figure 1B . CFA1 was an agonist for human TRPV1, M8, and to a lesser extent A1, a result previously described for TRPA1 (Deering-Rice et al., 2011) . Activation of TRPV1 by CFA1 produced a response 54 ± 7% that of the prototype agonist nonivamide, a response 47 ± 16% the prototype TRPM8 agonist icilin, and 18 ± 5% the prototype TRPA1 agonist AITC. Activation of TRPC4α, M2, and V2-4 by CFA1 was not observed.
This article has not been copyedited and formatted. The final version may differ from this version. The mechanism of TRPV1 activation by CFA1 was pursued further due to its robust response relative to nonivamide and the postulated role of TRPV1 in mediating respiratory injury by PM. The nature of the agonist responsible for CFA1-induced calcium flux (i.e., extracellular vs. intracellular CFA1 or insoluble vs. soluble CFA1 components) was compared in TRPV1-OE cells, with, and without, LJO-328 pre-treatment to increase the cell surface abundance of TRPV1 (Johansen et al., 2006) . LJO-328 pre-treated cells exhibited an approximate 6-fold increase in immunoreactive TRPV1 protein on the cell surface and were ~5-fold more responsive to CFA1 than non-pretreated cells (Figure 2A and B). CFA1-induced calcium flux in the LJO-328 pretreated TRPV1-OE cells was inhibited by co-treating cells with CFA1 and the TRPV1 antagonist LJO-328, as well as the non-selective cell surface calcium channel blocking agents EGTA and ruthenium red ( Figure 2B ). Manipulation of CFA1 by washing and solvent extraction was also used to illustrate that the solid components of CFA1 were the agonist of TRPV1. CFA1 recovered following overnight incubation and repeated (3X) washing with LHC-9 elicited a response that was 117 ± 19% that of CFA1 freshly suspended in LHC-9 (100 ± 23%) (p>0.05) and the clarified overnight media extract did not have agonist activity. Likewise, CFA1 washed 3X1h with 1 mL 1:1 chloroform:methanol, elicited a response that was 82 ± 12% that of fresh CFA1 (p>0.05), with no response observed for the dried and reconstituted organic extract residues. Of note, the residue did contain trace quantities of insoluble CFA1 material indicating the reduction in CFA1 potency observed by organic extraction may have been due to particle loss, and not partial removal of a soluble agonist.
The mechanism of TRPV1 activation by CFA1 was interrogated using site-directed mutagenesis of known functionally important amino acid residues of TRPV1 to identify key particle-protein interactions governing activity ( Figure 3A and C578A+N604A all exhibited a diminished response to CFA1, but mutation of the redox sensitive residue C621 (C621A) (Jin et al., 2004) and agonist/antagonist peptide binding residues A658 (A658P) and F660 (F660A) (Bohlen et al., 2010; Lin et al., 2011) , had no effect on TRPV1 activation by CFA1.
The role of TRPV1 in mediating pro-apoptotic and immunomodulatory In addition to the cell culture studies, the role of CFA1 in activating TRPV1 was assessed in an animal model. The induction of pro-apoptotic and pro-inflammatory responses in the intact mouse lung and airway tissue was assessed using intratracheal administration of nonivamide and CFA1. CF-1 mice were instilled intratracheally with nonivamide ( Figure 5A ) or CFA1 ( Figure   5B ) and the respiratory tissue was assayed for regional changes in GADD153, CXCL-1/KC, CXCL-2/MIP-2α, and IL-6 mRNA expression, relative to control values obtained from PBSinstilled mice; CXCL-1/KC and CXCL-2/MIP-2α constitute the functional equivalents of human IL-8. Significant induction of CXCL-1/KC, CXCL-2/MIP-2α, and IL-6 were generally observed in whole lung and bronchiole tissue 4h following nonivamide ( Figure 5A ) and CFA1 ( Figure 5B) treatment, compared to PBS instilled controls. Decreased expression of GADD153 was observed in the trachea, and to a lesser extent, in the bronchi of nonivamide-and CFA1-treated mice, as previously reported for nonivamide (Thomas et al., 2011) , and CXCL-1/KC was elevated in alveolar tissue, however, these responses were not statistically significant.
Histological analysis of lung tissue from CFA1-treated mice demonstrated CFA1 was retained in the bronchioles and alveoli (Figure 6 ), consistent with the gene expression data in Figure 5B ; no such material was observed in PBS-or nonivamide-treated mice (data not shown).
Finally, CFA1-induced changes in GADD153, CXCL-1/KC, CXCL-2/MIP-2α, and IL-6
were compared in wild-type C57BL/6 and TRPV1-/-C57BL/6 mice ( Figure 7) . No changes in GADD153 expression were detected, but significant increases in CXCL-1/KC, CXCL-2/MIP-2α, and IL-6 were observed in lungs of wild-type mice. CFA1-induced expression of CXCL-1/KC, CXCL-2/MIP-2α, and IL-6 was reduced in TRPV1-/-mice, but statistical significance was only achieved for CXCL-2/MIP-2α.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion:
This study investigated the hypothesis that TRPV1 is differentially activated by chemically and physically unique PM and that activation of TRPV1 by a PM agonist in lung cells and the respiratory tract would promote changes in the expression of pro-inflammatory and ER-stress associated genes that may contribute to pulmonary injury by inhaled PM. It is shown that TRPV1 is activated by some (CFA1, DEP, MUS), but not all PM; TRPM8 is also robustly activated by CFA1, and TRPA1 is slightly activated; activation of TRPV1 by CFA1 occurs via cell surface interactions between the solid components of CFA1 and specific amino acid residues of TRPV1 localized to the putative pore-loop region; and activation of TRPV1 by CFA1 is not exclusive in mouse lungs, but represents a pathway by which CFA1 impacts the expression of selected genes in lung epithelial cells and airway tissue. TRPV1 mediates the induction of several important pro-apoptotic and pro-inflammatory cytokine/chemokine genes in lung epithelial cells to in response to PM. However, while near complete inhibition of CFA1-induced calcium flux and gene expression changes were achieved using LJO-328 co-treatment of lung epithelial cells ( Figures 2B and 4A) , as shown by others using capsazepine and other forms of PM, only partial attenuation of gene induction was observed in TRPV1-/-mice relative to wild-type mice (Figure 7 ). These results, in conjunction with Figure 1B , suggest a possible role for neuronal TRPA1 or TRPM8 as additional mediators of lung inflammation and toxicity elicited by CFA1. Alternatively, pathways that were not evaluated in these studies may also contribute to the effects of CFA1 in the lung, particularly at the high dose of CFA1 used, where the precise contribution of TRPV1 may be poorly estimated.
Ongoing dose-response studies and future research employing more relevant exposure methods (e.g., inhalation of suspended PM for multiple days), combined with additional genetic and/or pharmacological inhibitors should provide a more complete model for TRPV1, A1, M8, and other PM sensors collectively contribute to the adverse effects of PM in the lung. Regardless, TRPV1 does play an important role in detecting CFA1 and initiating specific responses that likely contribute to the adverse effects of this and other similar PM in the respiratory tract.
Prior studies have also partially characterized the mechanism of activation of TRPV1 and demonstrated a requirement for cell surface contact and a net-negative surface charge on PM to elicit responses (Oortgiesen et al., 2000; Agopyan et al., 2003a; Agopyan et al., 2003b) . In this study, it is confirmed that TRPV1 activation by CFA1 occurs as a result of interactions between CFA1 and cell surface TRPV1. First, enrichment of TRPV1 at the cell surface enhanced both CFA1-induced calcium flux (Figures 2A and B ) and IL-6 and 8 mRNA expression ( Figure 4B ), with the latter serving as a "reporter assay" for cell surface TRPV1 activation, as supported by This article has not been copyedited and formatted. The final version may differ from this version. previous studies (Reilly et al., 2005; Johansen et al., 2006) . Second, chelation of calcium ions in the treatment media with EGTA, and co-treating cells with the cell-impermeable TRPV1 pore blocker ruthenium red, inhibited calcium flux comparable to that achieved using the selective cell-permeable TRPV1 antagonist LJO-328, which inhibits total cellular TRPV1 ( Figure 2B ).
Finally, the agonist activity of CFA1 was localized to the aqueous-and solvent-(1:1 chloroform:methanol) insoluble CFA1. Thus, unlike the activation of TRPA1 by electrophiles that can be extracted by alcohol and/or solvent treatments and are released from DEP upon cell contact (Deering-Rice et al., 2011), soluble CFA1-derived components do not activate TRPV1, providing a second specific mechanism by which two unique forms of environmental PM activate two specific TRP channels in the airway.
Consistent with prior proposed mechanisms of TRPV1 activation by negatively-charged PM (Oortgiesen et al., 2000; Veronesi et al., 2002; Agopyan et al., 2003a; Agopyan et al., 2003b; Veronesi et al., 2003) , and results in Figure 2 and 3B, it was demonstrated that mutation of the capsaicin binding site residue Y511 (Y511A), located on the intracellular loop between transmembrane segments 3 and 4, did not reduce TRPV1 activation by CFA1, despite completely inhibiting the response to nonivamide. Conversely, neutralization of the cell surface pore-loop residue E649 (E649A), which is predicted to reside at the entry to the ion pore domain at the membrane surface, forming a "base" of a cylindrical tetrameric pore region ( Figure 3A ), increased TRPV1 activation by CFA1 ~2-fold, relative to wild-type TRPV1. One interpretation of this result is that interactions between the pore-loop segment of TRPV1 (roughly residues 600-660), specifically E600, N604 (and/or the N-linked glycan attached at this position) (Wirkner et al., 2005) are facilitated as a result of a reduction in charge-charge repulsive forces that may occur between E649 and CFA1 ( Figure 3A) . However, this scenario does not fully This article has not been copyedited and formatted. The final version may differ from this version. explain the apparent roles for C578, E600, and N604 in CFA1-mediated activation of TRPV1.
As such, from the collective data in Figure 3 , reports that TRPV1, like other TRP channels, can be activated by mechanical mechanisms (Inoue et al., 2009) , and identification of a sequence of the extracellular pore loop residues that displaces upon thermal activation (Yang et al., 2010) , it is proposed that C578, E600, and N604 may be components of a "charge-and mechanosensitive" domain. Thus, the following model is proposed (refer to Figure 3A for a visual aid): 1) extracellular components of TRPV1 form a "basket-like structure" above the ion pore opening; 2) E600, and N604 reside at the membrane interface potentially constituting a flexible "hinge region" that must be displaced in order for CFA1 to activate TRPV1, and the presence of N604-linked glycans facilitate this process; 3) the base of the "basket-like structure"
interacts with CFA1 in a charge-dependent manner and neutralization of E649 leads to increased interaction by negatively-charged PM; and 4) mechanical movement of the cell surface "turret"
or "basket wall" components of TRPV1 are transduced into pore opening through interactions between C578 and yet undefined residues of the pore domain.
In summary, this study further illustrates that TRPV1 detects and differentially responds to select forms of environmental PM, and that TRPV1 activation contributes to several commonly cited cellular responses to PM including pro-apoptotic and pro-inflammatory gene induction in lung cells and airway tissue. It is anticipated that further elucidation of the contributions of TRPV1 and/or other related TRP channels to PM effects in the respiratory tract will reveal novel therapeutic opportunities to prevent and/or attenuate such effects in humans.
